Recently, it was demonstrated that EVs could be used as therapeutic drug carriers to deliver diversified anti‐cancer molecules, such as small interfering RNAs (siRNAs) or pharmacologically active compounds.[23] We next incorporated N‐WASP inhibitors 187‐1 or Wiskostatin into VAPA‐enriched LOs derived from VAPA‐overexpressing Hep3B cells or HCCLM3‐BM4 cells. The gene discussed is VAPA; the disease is cancer.